Undertreatment or Overtreatment With Statins: Where Are We?
Source : https://www.frontiersin.org/articles/10.3389/fcvm.2022.808712/full
Statins, in addition to healthy lifestyle interventions, are the cornerstone of lipid-lowering therapy. Other low-density lipoprotein (LDL)-lowering drugs include ezetimibe, bile acid sequestrants, and PCSK9 inhibitors. As new evidence emerges...
Relevance: This narrative review summarizes the evidence regarding the benefits of lipid-lowering drugs in reducing cardiovascular events, the pleiotropic effect of statins, real-world data on overtreatment and undertreatment of lipid-lowering therapies, and the changing LDL-C in targets in the clinical guidelines of dyslipidemias over the...
Share
-
Dr Hamid3yrseveral clinical studies have reported that, regardless of their lipid-lowering effects, statins reduce the levels of circulating pro-inflammatory molecules, such as levels of high-sensitivity C-reactive protein (hs-CRP)
Effect of PCSK9 Inhibitors on Hemostasis in Patients with Isolated Hypercholesterolemia - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35566668/
Our findings indicate that treatment with PCSK9 inhibitors has a multipotential effect on fibrinolysis and coagulation in patients with isolated hypercholesterolemia and that this medication may have some future benefits...
Conclusion: Our findings indicate that treatment with PCSK9 inhibitors has a multipotential effect on fibrinolysis and coagulation in patients with isolated hypercholesterolemia and that this medication may have some future benefits in patients who are statin-intolerant or contraindicated to statin use.
Share
-
Dr Hamid3yrThe purpose of this trial was to determine the efficacy of PCSK9 inhibitors alone in patients with isolated hypercholesterolemia and will help in treatment of patients
PCSK9 Inhibitors
Source : https://www.ncbi.nlm.nih.gov/books/NBK448100/
Familial hypercholesterolemia is characterized by extremely high total and LDL cholesterol levels, premature vascular disease, and tendon xanthomas. In most cases, this is due to a genetic mutation of the...
Relevance: This activity outlines the indications, mechanism of action, administration methods, significant adverse effects, contraindications, monitoring, and toxicity of PCSK9 inhibitors so providers can direct patient therapy to optimal outcomes in serum lipid management with these agents and obtain improved cardiovascular outcomes.
Share
Early Initiation of Evolocumab Treatment in Chinese Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Source : https://www.clinicaltherapeutics.com/article/S0149-2918(22)00149-7/fulltext
Despite the widespread use of evidence-based cardiovascular treatments, patients with acute coronary syndrome (ACS) remain at high risk for ischemic cardiovascular events.1-3 This risk is partly caused by elevated LDL-C...
Implications: Among Chinese patients who underwent PCI for ACS, the early initiation of evolocumab combined with statin treatment effectively reduced LDL-C levels and lowered the incidence of recurrent ischemic cardiovascular events, with satisfactory tolerability and safety. Chinese Clinical Trial Registry identifier:
Share
Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels in primary antiphospholipid syndrome. The multicenter ATHERO-APS study
Source : https://www.sciencedirect.com/science/article/abs/pii/S0896841122000403?via=ihub
The proprotein convertase subtilisin/kexin type 9 (PCSK9) is emerging as a novel cardiovascular risk factor. Levels of PCSK9 in thrombotic primary ant...
Conclusion: These preliminary data suggest that PCSK9 levels are increased in PAPS patients with arterial and recurrent thrombosis. Its role as a possible therapeutic target in PAPS needs further studies.
Share